Does Rallies show Form 4 insider transactions for REVB?

Yes. Rallies tracks REVB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is REVB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for REVB. It does not provide personalized investment advice.

REVB (Revelation Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Revelation Biosciences, Inc. Common Stock (REVB) is a publicly traded Healthcare sector company. As of May 21, 2026, REVB trades at $1.09 with a market cap of $4.06M and a P/E ratio of -0.04. REVB moved +0.00% today. Year to date, REVB is -67.52%; over the trailing twelve months it is -96.38%. Its 52-week range spans $0.88 to $241.92. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces REVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading REVB stock inside the company?

Recent REVB insider activity includes TIDMARSH GEORGE F sold 27.77K, TIDMARSH GEORGE F sold 1.84K, TIDMARSH GEORGE F sold 10.96K, TIDMARSH GEORGE F sold 1.43K, and TIDMARSH GEORGE F sold 4.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

REVB Key Metrics

Key financial metrics for REVB
Metric	Value
Price	$1.09
Market Cap	$4.06M
P/E Ratio	-0.04
EPS	$-23.95
Dividend Yield	0.00%
52-Week High	$241.92
52-Week Low	$0.88
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-8.91M
Gross Margin	0.00%

Recent REVB Insider Trades

TIDMARSH GEORGE F sold 27.77K (~$14.44K) on Dec 8, 2023.
TIDMARSH GEORGE F sold 1.84K (~$1.20K) on Oct 16, 2023.
TIDMARSH GEORGE F sold 10.96K (~$7.24K) on Oct 16, 2023.
TIDMARSH GEORGE F sold 1.43K (~$986.01) on Sep 28, 2023.
TIDMARSH GEORGE F sold 4.00K (~$2.96K) on Sep 18, 2023.

Latest REVB News

Revelation Biosciences Secures FDA OK for Phase 2/3 Gemini Trial, Boosts Cash to $14.1M — May 7, 2026
Revelation Biosciences Forms Five-Member Advisory Board for Phase 2/3 Gemini AKI Trial — Apr 6, 2026
Revelation Biosciences’ Gemini Demonstrates 60% Cytokine Reduction in CKD Patients — Mar 30, 2026
Revelation Biosciences Files Adaptive Phase 2/3 Plan, Bolsters $10.7M Cash Runway — Feb 26, 2026

REVB Analyst Consensus

1 analysts cover REVB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.

Common questions about REVB

Who is trading REVB stock inside the company?: Recent REVB insider activity includes TIDMARSH GEORGE F sold 27.77K, TIDMARSH GEORGE F sold 1.84K, TIDMARSH GEORGE F sold 10.96K, TIDMARSH GEORGE F sold 1.43K, and TIDMARSH GEORGE F sold 4.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for REVB?: Yes. Rallies tracks REVB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is REVB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for REVB. It does not provide personalized investment advice.